MP7
Based on 2 publication(s) in Google Scholar
MP7 (PDK1 inhibitor) is a phosphoinositide-dependent kinase-1 (PDK1) inhibitor.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.33%
- No. CAS: 1001409-50-2
- Fòrmula: C28H22F2N4O4
- Peso molecular:516.50
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) MP7
More
Actividad biológica
PDK1[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 786-0 | IC50 |
>30 μM
Compound: MP-7
|
Cytotoxicity against human 786-0 cells measured after 72 hrs by MTT assay
Cytotoxicity against human 786-0 cells measured after 72 hrs by MTT assay
|
[PMID: 34624821] |
| A-427 | EC50 |
>9 μM
Compound: 11
|
Antiproliferative activity against human A427 cells harboring KRAS mutant after 72 hrs by ATP ViaLight assay
Antiproliferative activity against human A427 cells harboring KRAS mutant after 72 hrs by ATP ViaLight assay
|
[PMID: 23448267] |
| A549 | EC50 |
>9 μM
Compound: 11
|
Antiproliferative activity against human A549 cells harboring KRAS mutant after 72 hrs by ATP ViaLight assay
Antiproliferative activity against human A549 cells harboring KRAS mutant after 72 hrs by ATP ViaLight assay
|
[PMID: 23448267] |
| A673 | IC50 |
>30 μM
Compound: MP-7
|
Cytotoxicity against human A673 cells measured after 72 hrs by MTT assay
Cytotoxicity against human A673 cells measured after 72 hrs by MTT assay
|
[PMID: 34624821] |
| BEAS-2B | IC50 |
96.36 μM
Compound: 6; MP7
|
Antiproliferative against human BEAS-2B cells measured after 48 hrs by CCK8 assay
Antiproliferative against human BEAS-2B cells measured after 48 hrs by CCK8 assay
|
[PMID: 36603508] |
| BT-474 | EC50 |
>9 μM
Compound: 11
|
Antiproliferative activity against human BT474 cells harboring PI3KCA mutant after 72 hrs by ATP ViaLight assay
Antiproliferative activity against human BT474 cells harboring PI3KCA mutant after 72 hrs by ATP ViaLight assay
|
[PMID: 23448267] |
| CAKI-1 | IC50 |
>30 μM
Compound: MP-7
|
Cytotoxicity against human CAKI-1 cells measured after 72 hrs by MTT assay
Cytotoxicity against human CAKI-1 cells measured after 72 hrs by MTT assay
|
[PMID: 34624821] |
| HCT-116 | EC50 |
>9 μM
Compound: 11
|
Antiproliferative activity against human HCT116 cells harboring PI3KCA/KRAS double mutant after 72 hrs by ATP ViaLight assay
Antiproliferative activity against human HCT116 cells harboring PI3KCA/KRAS double mutant after 72 hrs by ATP ViaLight assay
|
[PMID: 23448267] |
| HCT-116 | IC50 |
>30 μM
Compound: MP-7
|
Cytotoxicity against human HCT-116 cells measured after 72 hrs by MTT assay
Cytotoxicity against human HCT-116 cells measured after 72 hrs by MTT assay
|
[PMID: 34624821] |
| HFL1 | IC50 |
64.79 μM
Compound: 6; MP7
|
Antiproliferative against HLF1 cells measured after 48 hrs by CCK8 assay
Antiproliferative against HLF1 cells measured after 48 hrs by CCK8 assay
|
[PMID: 36603508] |
| HSC-T6 | IC50 |
36.23 μM
Compound: 6; MP7
|
Antiproliferative against rat HSC-T6 cells measured after 48 hrs by CCK8 assay
Antiproliferative against rat HSC-T6 cells measured after 48 hrs by CCK8 assay
|
[PMID: 36603508] |
| IGROV-1 | IC50 |
>30 μM
Compound: MP-7
|
Cytotoxicity against human IGROV-1 cells measured after 72 hrs by MTT assay
Cytotoxicity against human IGROV-1 cells measured after 72 hrs by MTT assay
|
[PMID: 34624821] |
| LNCaP | EC50 |
>9 μM
Compound: 11
|
Antiproliferative activity against PTEN-deficient human LNCAP cells after 72 hrs by ATP ViaLight assay
Antiproliferative activity against PTEN-deficient human LNCAP cells after 72 hrs by ATP ViaLight assay
|
[PMID: 23448267] |
| LS-513 | EC50 |
>9 μM
Compound: 11
|
Antiproliferative activity against human LS513 cells harboring KRAS mutant after 72 hrs by ATP ViaLight assay
Antiproliferative activity against human LS513 cells harboring KRAS mutant after 72 hrs by ATP ViaLight assay
|
[PMID: 23448267] |
| MCF7 | EC50 |
>9 μM
Compound: 11
|
Antiproliferative activity against human MCF7 cells harboring PI3KCA mutant after 72 hrs by ATP ViaLight assay
Antiproliferative activity against human MCF7 cells harboring PI3KCA mutant after 72 hrs by ATP ViaLight assay
|
[PMID: 23448267] |
| MCF7 | IC50 |
>30 μM
Compound: MP-7
|
Cytotoxicity against human MCF7 cells measured after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells measured after 72 hrs by MTT assay
|
[PMID: 34624821] |
| MDA-MB-231 | EC50 |
>9 μM
Compound: 11
|
Antiproliferative activity against human MDA-MB-231 cells harboring KRAS mutant after 72 hrs by ATP ViaLight assay
Antiproliferative activity against human MDA-MB-231 cells harboring KRAS mutant after 72 hrs by ATP ViaLight assay
|
[PMID: 23448267] |
| MDA-MB-453 | EC50 |
>9 μM
Compound: 11
|
Antiproliferative activity against human MDA-MB-453 cells harboring PI3KCA mutant after 72 hrs by ATP ViaLight assay
Antiproliferative activity against human MDA-MB-453 cells harboring PI3KCA mutant after 72 hrs by ATP ViaLight assay
|
[PMID: 23448267] |
| NCI-H1437 | EC50 |
>9 μM
Compound: 11
|
Antiproliferative activity against human NCI-H1437 cells after 72 hrs by ATP ViaLight assay
Antiproliferative activity against human NCI-H1437 cells after 72 hrs by ATP ViaLight assay
|
[PMID: 23448267] |
| NCI-H446 | EC50 |
>9 μM
Compound: 11
|
Antiproliferative activity against PTEN-deficient human NCI-H446 cells after 72 hrs by ATP ViaLight assay
Antiproliferative activity against PTEN-deficient human NCI-H446 cells after 72 hrs by ATP ViaLight assay
|
[PMID: 23448267] |
| NCI-H69 | IC50 |
13.9 μM
Compound: MP-7
|
Cytotoxicity against human NCI-H69 cells measured after 72 hrs by MTT assay
Cytotoxicity against human NCI-H69 cells measured after 72 hrs by MTT assay
|
[PMID: 34624821] |
| NCI-H82 | IC50 |
>30 μM
Compound: MP-7
|
Cytotoxicity against human NCI-H82 cells measured after 72 hrs by MTT assay
Cytotoxicity against human NCI-H82 cells measured after 72 hrs by MTT assay
|
[PMID: 34624821] |
| NRK-49F | IC50 |
40.39 μM
Compound: 6; MP7
|
Antiproliferative against rat NRK-49F cells measured after 48 hrs by CCK8 assay
Antiproliferative against rat NRK-49F cells measured after 48 hrs by CCK8 assay
|
[PMID: 36603508] |
| PC-3 | EC50 |
>9 μM
Compound: 11
|
Antiproliferative activity against PTEN-deficient human PC3 cells after 72 hrs by ATP ViaLight assay
Antiproliferative activity against PTEN-deficient human PC3 cells after 72 hrs by ATP ViaLight assay
|
[PMID: 23448267] |
| PC-3 | IC50 |
>30 μM
Compound: MP-7
|
Cytotoxicity against human PC-3 cells measured after 72 hrs by MTT assay
Cytotoxicity against human PC-3 cells measured after 72 hrs by MTT assay
|
[PMID: 34624821] |
| Rec1 | IC50 |
>30 μM
Compound: MP-7
|
Cytotoxicity against human REC1 cells measured after 72 hrs by MTT assay
Cytotoxicity against human REC1 cells measured after 72 hrs by MTT assay
|
[PMID: 34624821] |
| SK-N-MC | IC50 |
>30 μM
Compound: MP-7
|
Cytotoxicity against human SK-N-MC cells measured after 72 hrs by MTT assay
Cytotoxicity against human SK-N-MC cells measured after 72 hrs by MTT assay
|
[PMID: 34624821] |
| T47D | EC50 |
>9 μM
Compound: 11
|
Antiproliferative activity against human T47D cells harboring PI3KCA mutant after 72 hrs by ATP ViaLight assay
Antiproliferative activity against human T47D cells harboring PI3KCA mutant after 72 hrs by ATP ViaLight assay
|
[PMID: 23448267] |
| TC-32 | IC50 |
13.9 μM
Compound: MP-7
|
Cytotoxicity against human TC-32 cells measured after 72 hrs by MTT assay
Cytotoxicity against human TC-32 cells measured after 72 hrs by MTT assay
|
[PMID: 34624821] |
| U-87MG ATCC | EC50 |
>9 μM
Compound: 11
|
Antiproliferative activity against PTEN-deficient human U87 cells after 72 hrs by ATP ViaLight assay
Antiproliferative activity against PTEN-deficient human U87 cells after 72 hrs by ATP ViaLight assay
|
[PMID: 23448267] |
| U-87MG ATCC | IC50 |
>30 μM
Compound: MP7
|
Antiproliferative activity against human U87MG cells after 72 hrs
Antiproliferative activity against human U87MG cells after 72 hrs
|
[PMID: 27123901] |
| UMC-11 | EC50 |
>9 μM
Compound: 11
|
Antiproliferative activity against human UMC11 cells after 72 hrs by ATP ViaLight assay
Antiproliferative activity against human UMC11 cells after 72 hrs by ATP ViaLight assay
|
[PMID: 23448267] |
Cell counting of U87MG-derived glioma stem cells (GSCs) confirms that Alisertib and, to a minor extent, MP7 (PDK1 inhibitor) are able to decrease the number of viable cells. When combined together, GSC viability is further reduced with respect to single-treated cells. As observed in U87MG cells, when used at the highest concentrations (i.e., 1.5 μM Alisertib and 2.5 μM MP7), a significant enhancement in the number of dead cells is evidenced. Following 72 h treatment, MP7 alone does not show a significant inhibition of glioblastoma multiforme (GBM) proliferation. MP7 has been shown to have only minimal effects on monolayer cell growth in several cancer cell lines, with IC50 values in the micromolar range[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 1001409-50-2
-
Appearance Solid
-
Peso molecular 516.50
-
Fòrmula C28H22F2N4O4
-
Color Light yellow to yellow
-
SMILES
O=C(C1=CC=CN(CC2=CC=C(F)C(F)=C2)C1=O)N[C@H](C3=CC=CC=C3)COC4=CC=C(N5)C(NC5=O)=C4
-
Synonyms
PDK1 inhibitor
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Cell Rep Med
Insulin- and exercise-induced phosphoproteomics of human skeletal muscle identify REPS1 as a regulator of muscle glucose uptake. [Abstract]2025 Jun 17;6(6):102163. PMID: 40482643 -
EMBO J
2024 Oct;43(20):4752-4785. PMID: 39256562
Solvente y solubilidad
DMSO : ≥ 100 mg/mL (193.61 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.75 mg/mL (5.32 mM); Clear solution
This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocolo
The human GBM cells (i.e., U87MG, U343MG, or ANGM-CSS) or the respective GSCs are seeded and incubated for the indicated times with the indicated concentrations of SA16 (1 nM to 100 μM), MP7 (2.5 nM, 25 nM, 250 nM and 2.5 μM), or Alisertib. When indicated, cells are treated with MP7 and Alisertib in combination. To verify GSC chemoresistance, U87MG or GSCs are incubated with 50 μM TMZ for 72 h. For the long-term treatment of cells, NSC or complete medium containing drugs is replaced every 3 days. Cell proliferation is determined using the MTS assay: the dehydrogenase activity in active mitochondria reduces MTS to the soluble formazan product, whose absorbance at 490 nm is measured with an automated plate reader. The mean background from each test condition is subtracted, and the data are expressed as the percentage of untreated cells (control). IC50 values are derived from the sigmoid dose-response curve. The percentage of inhibition is calculated as 100% minus the percentage of cell proliferation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureza y Documentación
-
Ficha de datos (273 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9361 mL | 9.6805 mL | 19.3611 mL | 48.4027 mL |
| 5 mM | 0.3872 mL | 1.9361 mL | 3.8722 mL | 9.6805 mL | |
| 10 mM | 0.1936 mL | 0.9681 mL | 1.9361 mL | 4.8403 mL | |
| 15 mM | 0.1291 mL | 0.6454 mL | 1.2907 mL | 3.2268 mL | |
| 20 mM | 0.0968 mL | 0.4840 mL | 0.9681 mL | 2.4201 mL | |
| 25 mM | 0.0774 mL | 0.3872 mL | 0.7744 mL | 1.9361 mL | |
| 30 mM | 0.0645 mL | 0.3227 mL | 0.6454 mL | 1.6134 mL | |
| 40 mM | 0.0484 mL | 0.2420 mL | 0.4840 mL | 1.2101 mL | |
| 50 mM | 0.0387 mL | 0.1936 mL | 0.3872 mL | 0.9681 mL | |
| 60 mM | 0.0323 mL | 0.1613 mL | 0.3227 mL | 0.8067 mL | |
| 80 mM | 0.0242 mL | 0.1210 mL | 0.2420 mL | 0.6050 mL | |
| 100 mM | 0.0194 mL | 0.0968 mL | 0.1936 mL | 0.4840 mL |
MP7 Related Classifications
HY-14440 Related Classifications
Powered by Bioz